<DOC>
	<DOCNO>NCT01739634</DOCNO>
	<brief_summary>Diarrhea patient MTC ( Medullary Thyroid Cancer ) debilitating , case life threaten . Findings patient include volume depletion , renal insufficiency , electrolyte disorder . Diarrhea also lead increase cost care , reduce quality life , treatment delay . Not patient benefit conventional anti-diarrheal therapy . CASAD proven reduce diarrhea human animal . Clays water-binding effect , increase absorptive capacity intestinal mucosa , absorb excess cytokine possible mechanism diarrhea MTC . In study , investigate start 1 g CASAD three time day ameliorate severity diarrhea patient MTC . Diarrhea patient MTC debilitating , case life threaten . Findings patient include volume depletion , renal insufficiency , electrolyte disorder . We hypothesize add CASAD 3 grams/day reduce incidence ameliorate severity diarrhea patient MTC .</brief_summary>
	<brief_title>The Efficacy CASAD Patients With Diarrhea Related Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Patients medullary thyroid cancer Men woman ethnic racial group Diarrhea ( &gt; =3 loose bowel movement per day ) Duration diarrhea least 1 week Patients MEN 2b ( since patient may megacolon ) Patients take clay product History significant neurological psychiatric disorder would impede give consent , treatment , follow . Patients comply medication Patients whose current medication schedule would permit approximate 2 hour window administration CASAD schedule medication . Pregnancy lactation Patients receive systemic chemotherapy ( include tyrosine kinase inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Diarrhea</keyword>
	<keyword>Medullary thyroid cancer</keyword>
</DOC>